Latest 10-Q quarterly reports
NASDAQ
SharonAI Holdings Inc. has filed an amendment to its Q2 2026 Form 10-Q to correct errors in net loss per share and equity balances, reporting a substantial net loss for the period.
NASDAQ
GrowGeneration Corp. announced its second quarter 2026 financial results, showing a 5.5% increase in net sales but a continued net loss, alongside a decrease in gross profit margins for its Storage Solutions segment.
OQB
Tofutti Brands reported a significant decrease in net sales and a widening net loss for the second quarter of 2026, raising substantial doubt about its going concern status.
NASDAQ
SUMA Acquisition Corporation reports on its Q2 2026 financial status, highlighting interest income and operational costs as it continues its search for a business combination target.
OQB
SYRA
Syra Health CORPSyra Health Corp. announced a significant shift to profitability in its Q2 2026 report, driven by a 23% year-over-year revenue increase and improved gross margins.
NASDAQ
KOPN
Kopin CORPKopin Corporation's Q2 2026 filing reveals a shift to net income for the quarter but continued net loss for the six-month period, alongside ongoing litigation and identified material weaknesses in internal controls.
NYSE
ACM
AecomAECOM's Q3 filing reveals a net loss attributable to the company, a significant drop in gross profit, and a decrease in overall revenue compared to the prior year, though underlying revenue excluding pass-through costs showed growth.
NASDAQ
TRG Latin America Acquisitions Corp. files its Q2 2026 Form 10-Q, detailing its financial status as a SPAC and its ongoing search for a business combination.
NASDAQ
Wrap Technologies, Inc. announced its second-quarter 2026 financial results, showing a 103% increase in total revenues to $2.1 million, driven by a substantial rise in product sales, though technology-enabled services revenue declined.
AMEX
INUV
Inuvo, INCInuvo, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a substantial decrease in net revenue driven by a strategic reset in its Legacy Search business, while noting growth in its Audience Modeling segment.
NASDAQ
Mineralys Therapeutics, Inc. (MLYS) reports a substantial increase in R&D expenses driven by a $200 million upfront payment for a license amendment, alongside securing a $100 million term loan and raising capital through equity offerings.
NASDAQ
Auburn National Bancorporation announced a 34% increase in net earnings for the first six months of 2026, driven by higher interest income and improved net interest margin.
NASDAQ
Firefly Aerospace Inc. announced a substantial increase in revenue for the second quarter of 2026, driven by its Spacecraft Solutions segment and the integration of SciTec, though net losses widened.
NASDAQ
Spartacus Acquisition Corp. II reports on its Q2 2026 activities, highlighting its focus on the TMT sector for a future business combination and detailing its financial position.
NASDAQ
PXLW
Pixelworks, INCPixelworks, Inc. (PXLW) files its Q2 2026 Form 10-Q, detailing a substantial revenue decrease and operational losses, offset by a significant gain from the sale of its semiconductor business.
NASDAQ
KLX Energy Services Holdings, Inc. reported its second quarter 2026 financial results, showing a net loss and detailing a significant upcoming rights offering to address financial obligations.
NASDAQ
Abony Acquisition Corp. I reports continued growth in its trust account due to interest income, while actively searching for a business combination target.
NASDAQ
Aardvark Therapeutics reports significant clinical trial setbacks for ARD-101, including an FDA clinical hold and trial terminations, leading to increased operating expenses and net losses.
NASDAQ
Sanara MedTech Inc. (SMTI) filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased net revenue and Adjusted EBITDA, alongside the significant announcement of a merger agreement with MiMedx Group, Inc.
NYSE
Rithm Acquisition Corp. reports its financial results for the quarter ended June 30, 2026, highlighting interest income and ongoing efforts to secure a business combination.
NASDAQ
BWEN
Broadwind, INCBroadwind, Inc. announced a significant increase in revenue and gross profit for the second quarter of 2026, driven by strong performance in its Gearing and Industrial Solutions segments, despite a continued net loss.
NASDAQ
Mount Logan Capital Inc. reported a significant decline in revenues and net income for the second quarter of 2026, with Asset Management revenues down 32% and net loss widening.
NASDAQ
EML
Eastern COThe Eastern Company's Q2 2026 Form 10-Q reveals a substantial bargain purchase gain from recent acquisitions, offsetting a decline in net sales and demonstrating improved operational cash flow.
NASDAQ
Eloxx Pharmaceuticals, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased operating expenses, significant net losses, and a substantial accumulated deficit, while also highlighting a recent public offering and Nasdaq uplisting.
NASDAQ
National CineMedia's Q2 2026 filing shows a 12.7% revenue increase to $58.4 million, but the company continues to report net losses.
NYSE
Rice Acquisition Corporation 3 reports continued growth in its trust account income for the second quarter of 2026, while still in the process of identifying a business combination target.
OQB
NLST
Netlist INCNetlist Inc. announced a substantial increase in net sales and a return to net income for the quarter ended June 27, 2026, driven by strong demand and strategic agreements.
NASDAQ
INTZ
Intrusion INCIntrusion Inc. filed its Q2 2026 10-Q, revealing a substantial decrease in revenue and a widening net loss, while also announcing the acquisition of VigilAigent.
NASDAQ
Pono Capital Four, Inc. reported net income for the second quarter of 2026 driven by trust account investments, while acknowledging substantial doubt about its ability to continue as a going concern.
NASDAQ
NGNE
Neurogene INCNeurogene Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D expenses and net losses, while highlighting positive long-term clinical data for its lead candidate, NGN-401.